Victory Capital Management
AGIO icon

Victory Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Victory Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Sell
6,441
-12,674
-66% -$384K ﹤0.01% 2223
2026
Q1 		$647K Sell
19,115
-8,582
-31% -$243K ﹤0.01% 1972
2025
Q4 		$754K Sell
27,697
-2,535
-8% -$88.9K ﹤0.01% 1939
2025
Q3 		$1.21M Buy
30,232
+818
+3% +$30.8K ﹤0.01% 1747
2025
Q2 		$978K Buy
29,414
+20,630
+235% +$625K ﹤0.01% 1862
2025
Q1 		$257K Buy
8,784
+1,964
+29% +$65.2K ﹤0.01% 2167
2024
Q4 		$224K Sell
6,820
-184
-3% -$8.64K ﹤0.01% 2202
2024
Q3 		$311K Sell
7,004
-154
-2% -$6.99K ﹤0.01% 2128
2024
Q2 		$309K Sell
7,158
-52
-0.7% -$1.88K ﹤0.01% 2092
2024
Q1 		$211K Buy
+7,210
New +$193K ﹤0.01% 2209
2023
Q2 		– Sell
-52,670
Closed -$1.21M – 2515
2023
Q1 		$1.21M Sell
52,670
-834,624
-94% -$22.2M ﹤0.01% 1594
2022
Q4 		$24.9M Buy
887,294
+109,998
+14% +$3.1M 0.03% 693
2022
Q3 		$22M Buy
+777,296
New +$20.8M 0.03% 763
2022
Q1 		– Sell
-12,227
Closed -$402K – 2725
2021
Q4 		$402K Sell
12,227
-40,899
-77% -$1.65M ﹤0.01% 2265
2021
Q3 		$2.45M Buy
53,126
+45,364
+584% +$2.19M ﹤0.01% 1540
2021
Q2 		$428K Sell
7,762
-1,058
-12% -$59.2K ﹤0.01% 2274
2021
Q1 		$455K Sell
8,820
-230
-3% -$11.4K ﹤0.01% 2243
2020
Q4 		$392K Buy
9,050
+1,360
+18% +$53.8K ﹤0.01% 2184
2020
Q3 		$269K Buy
7,690
+160
+2% +$7.01K ﹤0.01% 2191
2020
Q2 		$403K Sell
7,530
-66
-0.9% -$3.06K ﹤0.01% 2059
2020
Q1 		$270K Sell
7,596
-1,952
-20% -$90.2K ﹤0.01% 2058
2019
Q4 		$456K Buy
9,548
+2,888
+43% +$109K ﹤0.01% 2051
2019
Q3 		$216K Buy
+6,660
New +$276K ﹤0.01% 2195
2017
Q1 		– Sell
-6,750
Closed -$282K – 1801
2016
Q4 		$282K Buy
+6,750
New +$354K ﹤0.01% 1348

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Victory Capital Management's AGIO Position: Q2 2026 in Review

Victory Capital Management reduced its Agios Pharmaceuticals (AGIO) stake by 66% in Q2 2026, selling an estimated $384K and leaving 6,441 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #2223.

Victory Capital Management first reported a position in AGIO in Q4 2016 and has held it in 24 quarters since. The position peaked at $24.9M in Q4 2022. 239 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Victory Capital Management held 6,441 shares of Agios Pharmaceuticals worth $239K as of Q2 2026.
  • Victory Capital Management sold 12,674 Agios Pharmaceuticals shares in Q2 2026, an estimated $384K.
  • Agios Pharmaceuticals made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2223 holding.
  • Victory Capital Management first reported a position in Agios Pharmaceuticals in Q4 2016 and has held it in 24 quarters since.
  • Victory Capital Management's Agios Pharmaceuticals position peaked at $24.9M in Q4 2022.
  • 239 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.